Immunomodulatory treatment for amyotrophic lateral sclerosis/ motor neuron disease (Protocol)

Malhotra, H.S. and Singh, B.P. and Kumar, N. and Garg, R.K. and Kirubakaran, R. and Emsley, H.C.A. and Chhetri, S.K. and Mulvaney, C.A. and Villanueva, G. (2022) Immunomodulatory treatment for amyotrophic lateral sclerosis/ motor neuron disease (Protocol). Cochrane Database of Systematic Reviews, 2022 (6). ISSN 1469-493X

[img]
Text (Malhotra_et_al-2022-Cochrane_Database_of_Systematic_Reviews)
Malhotra_et_al_2022_Cochrane_Database_of_Systematic_Reviews.pdf - Published Version
Restricted to Repository staff only until 24 June 2023.
Available under License Creative Commons Attribution-NonCommercial.

Download (169kB)

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the efficacy and harms or adverse events of immunomodulatory therapies in people with ALS compared with a placebo, no additional treatment, or a standard-of-care protocol (with or without riluzole, edaravone, or both).

Item Type:
Journal Article
Journal or Publication Title:
Cochrane Database of Systematic Reviews
Additional Information:
This is the version of record of the following protocolMalhotra HS, Singh BP, Kumar N, Garg RK, Kirubakaran R, Emsley HCA, Chhetri SK, Mulvaney CA, Villanueva G. Immunomodulatory treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2022, Issue 6. Art. No.: CD013945. DOI: 10.1002/14651858.CD013945. Accessed 12 September 2022 which has been published in final form at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013945/full This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
Uncontrolled Keywords:
/dk/atira/pure/subjectarea/asjc/2700
Subjects:
ID Code:
173201
Deposited By:
Deposited On:
12 Sep 2022 12:40
Refereed?:
Yes
Published?:
Published
Last Modified:
12 Sep 2022 12:40